Previous 10 | Next 10 |
Initial Phase 1/2 data presented at the 63 rd American Society of Hematology (ASH) Annual Meeting and Exposition Phase 1/2 study of NEXI-002 as a monotherapy in patients with relapsed/refractory multiple myeloma patients who have failed ≥3 prior lines of thera...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Neximmune (NASDAQ:NEXI): Q3 GAAP EPS of -$0.65 in-line. Cash, cash equivalents and marketable securities of $93.2M. Press Release For further details see: Neximmune EPS in-line
Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated by year end 2021 and first half 2022 Announced collaboration with Yale University Department of Immunobiology to explore use of AIM INJ in regard to re...
GAITHERSBURG, Md., Nov. 08, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today annou...
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today annou...
Gainers: Alzamend Neuro (NASDAQ:ALZN) +52%, Progenity (NASDAQ:PROG) +18%, OptimizeRx (NASDAQ:OPRX) +15%, Atea Pharmaceuticals (NASDAQ:AVIR) +14%, Perrigo (NYSE:PRGO) +11%. Losers: Corvus Pharmaceuticals (NASDAQ:CRVS) -15%, NuCana (NASDAQ:NCNA)...
GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today anno...
GAITHERSBURG, Md., Sept. 10, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today anno...
Announcing first solid tumor indication in HPV associated-malignancies – NEXI-003 Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated in the second half of 2021 GAITHERSBURG, Md., Aug. 0...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...